resin with advanced performance - kaneka kancap™ · kaneka kancapatm 3g represents a new...
TRANSCRIPT
KANEKA KanCapATM 3G represents a new
cellulose-based protein A resin with a high
dynamic binding capacity and an outstanding
impurity removal characteristics.
KANEKA KanCapATM 3G is the best choice for
purifying monoclonal antibodies and their
Fc fusion derivatives under milder elution
conditions with increased purity.
> Enhanced binding capacity
> Excellent elution profi le
> Unique impurity removal properties
Protein A Affi nity Chromatography Resin
Resin with advanced performance
KANEKA KanCapA 3G Formats TM
3.4
3.6
3.8
4.0
4.2
4.4
Elu
tio
n p
H
A (humanized IgG1)
B (human IgG2)
C (Fc-fusion)
D (chimeric IgG1)
E (chimeric IgG1)
F (human IgG2)
G (humanized IgG1)
H (humanized IgG1)
KANEKA KanCapA™ 3G
Competitor A
KANEKA KanCapA™ 3G Performance
Enhanced binding capacity
Unique impurity removal properties
Mild elution pH
0
20
40
60
80
0 2 4 6 8 10
DB
C a
t 5
% b
reak
thro
ug
h (m
g lg
G /
mL
re
sin
)
Residence time (min.)
KANEKA
KanCapA™ 3G
Competitor A
KANEKA
KanCapA™
Figure 2 Comparison of the elution pH of KANEKA KanCapA™3G to competitor A. Elution pH was determined by a linear pH gradient elution using citrate buffer from pH 6 to pH 3.
KANEKA KanCapATM 3G shows enhanced binding capacity, mainly at longer residence times, which makes it suitable for monoclonal antibody purification from high titer feedstocks.
KANEKA KanCapA™ 3G has a better potential for impurity removal compared to current resins available on the market.
KANEKA KanCapATM 3G’s ligand was designed for efficient elution of monoclonal antibodies and their Fc fusion derivatives under mild acidic conditions.
mAb (IgG1)
Figure 1 Residence time vs DBC (Polyclonal Human IgG)
Figure 3 Efficient HCP (left) and aggregates (right) separation during mAb elution by linear pH gradient. Monomer Peak Host cell protein (HCP) Aggregate Molecules: IgG1 (CCCF), Load: 5 mg/mL-resin Elution: 50 mM Citrate buffer, (pH 4.5–› 3, gradient, 10 CV)
Japan Kaneka Corporation1-12-32, Akasaka, Minato-ku,Tokyo 107-6028, [email protected]
USA Kaneka US Innovation Center7979 Gateway Blvd., Suite 220Newark, CA [email protected]
EuropeKaneka Eurogentec S.A. Rue du bois Saint-Jean, 144102 Seraing, [email protected]
Contact information
Disclaimers : All experimental data are provided “as is”, without any warranty of accuracy or completeness.
KANEKA KanCapATM is a trademark of KANEKA ©2019 Kaneka Corporation, Japan - All rights reserved
0
4,000
8,000
12,000
16,000
1 2 3 4 5 6 7 8 9 10 11
pH 3.8
0
20
40
60
80
1 2 3 4 5 6 7 8 9 10 11
pH 3.7
Aggregate removalKANEKA KanCapA™ 3G Competitor A
Fraction #
mA
b m
on
om
er
con
cen
trat
ion
(S
EC
are
a)
Re
lati
ve d
istr
ibu
tio
n o
f ag
gre
gat
e (
/%)
0
4,000
8,000
12,000
16,000
1 2 3 4 5 6 7 8 9 10 11
mA
b m
on
om
er
con
cen
trat
ion
(S
EC
are
a) pH 3.8
0
20
40
60
80
1 2 3 4 5 6 7 8 9 10 11
pH 3.7
Fraction #
Host cell protein removalKANEKA KanCapA™ 3G Competitor A
Re
lati
ve d
istr
ibu
tio
n o
f H
CP
(/%
)